Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

Table 5 Post-treatment changes in lymphocytes

	Post-treatment percentage change from baseline (mean ± SD)
Parameter	6 weeks	10 weeks	18 weeks	32 weeks
Lymphocytes	n = 14	n = 12	n = 11	n = 7
B cells	-54%^a ± 25%	-45%^a ± 47%	-39%^a ± 23%	-31%^a ± 33%
T cells	2% ± 36%	-6% ± 34%	1% ± 13%	-5% ± 19%

^aDenotes statistical significance of the observed median change-from-baseline value with P ≤ 0.05 by Wilcoxon signed rank test. None of the changes from baseline in T cells was statistically significant. SD, standard deviation.

ISSN: 1478-6362